Summary
Following the reintroduction of H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act, and several other bills featuring drug pricing provisions, the Wynne Health Group has developed a chart (attached) that examines the major proposals currently being considered in the 117th Congress. Specifically, the chart compares the legislative proposals across a number of policy dimensions, including:
- Drug price negotiations;
- Part D redesign;
- Inflation rebates;
- International mechanisms;
- Anticompetitive behavior; and
- Manufacturing reporting.
Though it has not been reintroduced, the chart also features S.2543, the Prescription Drug Pricing Reduction Act to provide an additional reference point for comparison regarding provisions on Part D redesign, inflation rebates, and manufacturing reporting.